Time to blood count recovery
| Cohort . | CR . | PR . | ||||
|---|---|---|---|---|---|---|
| Subjects . | Platelets . | ANC . | Subjects . | Platelets . | ANC . | |
| No. . | Days, median (range) . | No. . | Days, median (range) . | |||
| A1 | 3 | 22 (21-23) | 21 (21-39) | 2 | 22 (20-24) | 34 (27-41) |
| B1 | 3 | 22 (20-26) | 30 (24-35) | 1 | 23 (23-23) | 30 (30-30) |
| A2 | 2 | 24 (22-26) | 26 (24-28) | 2 | 23 (21-24) | 32 (28-35) |
| B2 | 2 | 29 (22-36) | 33 (30-36) | 1 | 23 (23-23) | 22 (22-22) |
| A3 | 3 | 22 (20-26) | 23 (23-27) | 2 | 27 (25-28) | 27 (21-33) |
| B3 | 4 | 24 (21-27) | 23 (19-29) | 1 | 28 (28-28) | 37 (37-37) |
| All | 17 | 22 (20-36) | 24 (19-39) | 9 | 24 (20-28) | 30 (21-41) |
| Cohort . | CR . | PR . | ||||
|---|---|---|---|---|---|---|
| Subjects . | Platelets . | ANC . | Subjects . | Platelets . | ANC . | |
| No. . | Days, median (range) . | No. . | Days, median (range) . | |||
| A1 | 3 | 22 (21-23) | 21 (21-39) | 2 | 22 (20-24) | 34 (27-41) |
| B1 | 3 | 22 (20-26) | 30 (24-35) | 1 | 23 (23-23) | 30 (30-30) |
| A2 | 2 | 24 (22-26) | 26 (24-28) | 2 | 23 (21-24) | 32 (28-35) |
| B2 | 2 | 29 (22-36) | 33 (30-36) | 1 | 23 (23-23) | 22 (22-22) |
| A3 | 3 | 22 (20-26) | 23 (23-27) | 2 | 27 (25-28) | 27 (21-33) |
| B3 | 4 | 24 (21-27) | 23 (19-29) | 1 | 28 (28-28) | 37 (37-37) |
| All | 17 | 22 (20-36) | 24 (19-39) | 9 | 24 (20-28) | 30 (21-41) |
Data are shown for responders. By definition, all responders had a complete hematologic response. There were no statistically significant differences in the time of nadir between treatment arms, dose levels, or cohorts.